# Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

Study · id `cardio:ct-nct02342444` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02342444](<https://clinicaltrials.gov/study/NCT02342444>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02342444

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 606 participants.

## Technical summary

Registry record NCT02342444. Randomized; no masking; primary purpose prevention. Start 2014-02 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 606 participants (planned count; ClinicalTrials.gov record NCT02342444, source copy `cardio:ctgov-nct02342444-2024-04-03`, retrieved 2026-10-31)
- Started: 2014-02 (actual) (ClinicalTrials.gov record NCT02342444, source copy `cardio:ctgov-nct02342444-2024-04-03`, retrieved 2026-10-31)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT02342444, source copy `cardio:ctgov-nct02342444-2024-04-03`, retrieved 2026-10-31)
- Completion: 2025-03-31 (anticipated) (ClinicalTrials.gov record NCT02342444, source copy `cardio:ctgov-nct02342444-2024-04-03`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02342444, source copy `cardio:ctgov-nct02342444-2024-04-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02342444-2024-04-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- Condition: Trauma
- Condition: Surgery
- Condition: Deep Vein Thrombosis (DVT)
- Condition: Thromboembolic Events
- Intervention (Drug): Enoxaparin Sodium Injection 30 mg BID
- Intervention (Drug): Enoxaparin Sodium Injection 40 mg QD
- Lead sponsor: Oregon Health and Science University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Oregon Health and Science University (`cardio:org-oregon-health-and-science-university`)

## Provenance

Content hash: f851d6e11c499d5ff6adad9396083607c2c873c07f7de9fd3cb112a345af4af6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
